TP53 and acute myeloid leukemia: A phase Ib/II clinical trial published by Sallman et al. in 2021 included 55 participants (44 with MDS or MDS/MPN and 11 with AML) with mutant TP53 and evaluated the safety and efficacy of adding eprenetapopt to HMA therapy.